Relay Therapeutics
Yahoo Finance • 16 hours ago
Raymond James Updates Healthcare Top Picks for October
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeu... Full story
Yahoo Finance • 2 months ago
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented initial positive clin... Full story
Yahoo Finance • 2 months ago
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story
Yahoo Finance • 4 months ago
Relay Therapeutics Prices $275 Mln Offering Of Shares At $12 Per Share
(RTTNews) - Relay Therapeutics, Inc. (RLAY), a clinical-stage, small-molecule precision medicine company, priced its public offering of 22.92 million shares of common stock at a public offering price of $12 per share. The gross proceeds fr... Full story
Yahoo Finance • 4 months ago
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and ge... Full story
Yahoo Finance • 4 months ago
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
Rising Bond Yields Weigh on Stocks
The S&P 500 Index ($SPX) (SPY) today is down -0.68%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.34%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.95%. June E-mini S&P futures (ESM26) are down -0.75%, and June E-mini Na... Full story
Yahoo Finance • 4 months ago
Stocks Pressured by Tech Weakness and Rising Bond Yields
The S&P 500 Index ($SPX) (SPY) today is down -0.35%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.45%. June E-mini S&P futures (ESM26) are down -0.40%, and June E-mini Na... Full story
Yahoo Finance • 5 months ago
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
SB Investment Advisers (UK) Ltd reported a sale of 2,168,884 shares of Vir Biotechnology(NASDAQ:VIR) in its May 15, 2026, SEC filing, an estimated $17.28 million trade based on quarterly average pricing. What happened According to an SEC... Full story
Yahoo Finance • 5 months ago
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Quick Read All three biotechs have dense 2026 clinical and regulatory milestone calendars that can drive outsized share movements, with cash runways stretching into 2028-2029 and strong analyst support despite pre-revenue status and binar... Full story
Yahoo Finance • 5 months ago
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on
[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story
Yahoo Finance • 7 months ago
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story
Yahoo Finance • 7 months ago
Erasca, Inc. (ERAS): A Bull Case Theory
We came across a bullish thesis on Erasca, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ERAS. Erasca, Inc.'s share was trading at $12.39 as of February 19th.Cidara (CDTX) Climbs 105% on $... Full story
Yahoo Finance • 7 months ago
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story
Yahoo Finance • 10 months ago
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways... Full story
Yahoo Finance • 11 months ago
Relay Therapeutics GAAP EPS of -$0.43 misses by $0.02
* Relay Therapeutics press release [https://seekingalpha.com/pr/20297824-relay-therapeutics-reports-third-quarter-2025-financial-results-and-corporate-updates] (RLAY [https://seekingalpha.com/symbol/RLAY]): Q3 GAAP EPS of -$0.43 misses by... Full story
Yahoo Finance • 11 months ago
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story
Yahoo Finance • last year
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week
Key Points An analyst initiated coverage of the biotech. Not only does he consider it a buy, he's also designated it as one of his firm's top picks.10 stocks we like better than Relay Therapeutics › Precision medicine specialist Relay Th... Full story
Yahoo Finance • last year
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story
Yahoo Finance • last year
Relay Therapeutics’ SWOT analysis: AI-driven biotech’s stock faces pivotal phase
Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotechnology company specializing in precision medicine and AI-driven drug discovery, stands at a critical juncture in its development. With its lead candidate RLY-2608 progressing through clinica... Full story
- T